Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
3 DCMN researchers among most cited scientists10 December 2018
Christian Beckmann, Jan Buitelaar and Barbara Franke made it to this year’s list of highly cited researchers. Scientists in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.read more
AFIRM grant for Regenerative Biomaterials10 December 2018
Within the Armed Forces Institute of Regenerative Medicine (AFIRM), a large federally funded US institution committed to develop clinical Regenerative Medicine therapies for wounded warriors, additional funding has been assigned to the group Regenerative Biomaterials (Dept. of Dentistry).read more
Mangala Srinivas elected chair of the Young Academy of Europe7 December 2018
The YAE is a pan-European initiative of outstanding young scientists for networking, scientific exchange and science policy.read more
Two grants for Rheumatology awarded by Dutch Arthritis Association7 December 2018
Two projects of Arjen Blom and Peter van Lent, theme Inflammatory diseases, were granted by the Dutch Arthritis Association (ReumaNederland) (€ 160,000 per project).read more
Minister pleads for a better use of big data in healthcare6 December 2018
The minister for medical care and sport, Bruno Bruins, sent his recommendation regarding the use of big data in healthcare to the House of Representatives. In order to securely share data, the Personal Health Train project was established. Peter-Bram ‘t Hoen is one of the project leaders.read more
A personal touch of Elianne Bulthuis6 December 2018
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t! This week: Elianne Bulthuisread more